Alvotech's AVT03 Biosimilar Approved in Europe for Osteoporosis and Cancer Treatment.
ByAinvest
Monday, Nov 24, 2025 5:38 am ET1min read
ALVO--
• Alvotech receives EC approval for AVT03, a biosimilar to Prolia and Xgeva. • Denosumab market valued at $1.2 billion across all indications in Europe. • AVT03 approved in two presentations for osteoporosis and cancer treatment. • Biosimilar option to broaden access to established treatments in Europe.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet